Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: A systematic review and meta-analysis*

@article{Kalil2010LinezolidVV,
  title={Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: A systematic review and meta-analysis*},
  author={A. Kalil and M. Murthy and E. Hermsen and F. K. Neto and Junfeng Sun and M. Rupp},
  journal={Critical Care Medicine},
  year={2010},
  volume={38},
  pages={1802-1808}
}
INTRODUCTION Compared with glycopeptides, linezolid achieves higher lung epithelial lining fluid concentrations, which may correlate with improved efficacy in the treatment of nosocomial pneumonia. [...] Key MethodMETHODS Prospective randomized trials that tested linezolid vs. vancomycin or teicoplanin for treatment of nosocomial pneumonia were included. Heterogeneity was analyzed by I(2) and Q statistics. Meta-analysis relative risks were based on fixed and random-effects models.Expand
Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: meta-analysis of randomised controlled trials
TLDR
Although linezolid was more effective in eradicating microbiology than glycopeptide antibiotics for nosocomial pneumonia patients, it did not demonstrate superiority in clinical cure. Expand
Efficacy and safety of linezolid versus teicoplanin for the treatment of MRSA infections: a meta-analysis.
TLDR
The recommendation is that the decision about treating MRSA infections with linezolid or with teicoplanin should depend on local availability, patient population, dosage regimens, costs and safety, rather than presumed differences in efficacy. Expand
Linezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis
TLDR
It is suggested that linezolid is not superior to vancomycin with respect to both clinical and microbiological cure rates in patients with MRSA NP. Expand
Comparison of efficacy of linezolid and vancomycin for treatment of hospitalacquired pneumonia: A meta-analysis
TLDR
The efficacy and safety of linezolid and vancomycin was similar for treatment of hospital-acquired pneumonia, while the thrombocytopenia caused by lineZolid was significantly higher than that by vancomYcin. Expand
Linezolid versus vancomycin for meticillin-resistant Staphylococcus aureus infection: a meta-analysis of randomised controlled trials.
TLDR
Evidence is provided that linezolid possesses significant advantages compared with vancomycin and may be a superior alternative for MRSA-related infection. Expand
Pharmacotherapy for Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia
TLDR
Based on the currently available evidence and cost-effectiveness, vancomycin should continue to be the drug of choice for most patients with nosocomial MRSA pneumonia, and Linezolid is a reasonable alternative for patients with treatment failure while receiving vancomYcin. Expand
Linezolid Versus Vancomycin in the Empiric Treatment of Nosocomial Pneumonia: A Cost-Utility Analysis Incorporating Results from the ZEPHyR Trial.
  • C. Collins, A. Schwemm
  • Medicine
  • Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
  • 2015
TLDR
Linezolid may be a cost-effective alternative to vancomycin in the empiric treatment of patients with suspected MRSA nosocomial pneumonia; however, results of the model were highly variable on a number of important variables and assumptions including mortality differences and time frame analyzed. Expand
The Efficacy and Safety of Linezolid and Glycopeptides in the Treatment of Staphylococcus aureus Infections
TLDR
Based on the analysis of the pooled data of randomized control trials, linezolid should be a better choice for treatment of patients with S. aureus infections, especially in SSTIs patients than glycopeptides, however, the risk of haematological and gastrointestinal events should be taken into account according to the characteristics of the specific patient populations. Expand
Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study.
TLDR
Clinical response at EOS in the PP population was significantly higher with linezolid than with vancomycin, although 60-day mortality was similar, and survival and safety were also evaluated. Expand
Meta-analysis of vancomycin versus linezolid in pneumonia with proven methicillin-resistant Staphylococcus aureus.
TLDR
A systematic review and comparative meta-analysis of VCM and LZD efficacy against proven MRSA pneumonia using RCTs and CSs conducted in worldwide would be one of robust evidences to corroborate the guidelines by IDSA for the treatment of proven MRsa pneumonia. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 41 REFERENCES
Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study.
TLDR
Linezolid is a well-tolerated, effective treatment for adults with gram-positive nosocomial pneumonia and Eradication rates of methicillin-resistant Staphylococcus aureus and safety evaluations were similar between treatment groups. Expand
Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections.
TLDR
Linezolid was clinically superior to teicoplanin in the treatment of Gram-positive infections in a randomized, controlled, open-label, multicentre study of 430 patients with suspected or proven Gram- positive infection. Expand
Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials.
TLDR
Although linezolid is more effective than its comparators for the empirical treatment of selected patients, several points, such as the use of less potent antistaphylococcal beta-lactams, the same all-cause mortality, and the higher probability of thrombocytopenia, should be taken into account and may limit the use to specific patient populations or infections that are difficult to treat with other antibiotics. Expand
Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.
TLDR
Initial therapy with linezolid was associated with significantly better survival and clinical cure rates than was vancomycin in patients with nosocomial pneumonia due to MRSA. Expand
Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study.
TLDR
Linezolid has similar safety and efficacy to teicoplanin in treating Gram-positive infections in the critically ill and initial clearance of methicillin-resistant Staphylococcus aureus and MRSA colonization suggests better skin and mucosal penetration. Expand
Effect of linezolid compared with glycopeptides in methicillin-resistant Staphylococcus aureus severe pneumonia in piglets.
TLDR
LZD AMT was associated with lower pathology score, better survival, and a trend to better clearance of MRSA, not attributable exclusively to pharmacokinetic or pharmacodynamic reasons. Expand
Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan.
TLDR
Linezolid is as effective as vancomycin for the treatment of MRSA infections and may be more effective in achieving microbiological eradication and laboratory data showed a mild reversible trend towards lower platelet counts. Expand
Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer.
TLDR
Linezolid demonstrated efficacy and similar safety outcomes equivalent to those for vancomycin in febrile neutropenic patients with cancer and all subsets. Expand
Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children
TLDR
Linezolid was well-tolerated and as effective as vancomycin in treating serious Gram-positive infections in children and significantly fewer linezolid-treated patients had drug-related adverse events than did vancomYcin- treated patients. Expand
Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.
TLDR
Hospitalized adults with known or suspected methicillin-resistant Staphylococcus aureus infections were treated with linezolid or vancomycin, and both regimens were well tolerated, with similar rates of adverse events. Expand
...
1
2
3
4
5
...